HONGLI GROUP INC
HLPNASDAQTrading Snapshot
- Day Range
- $2.44 – $2.46
- 52-Week Range
- $0.34 – $2.48
- Volume
- $3.10B
- Avg Volume
- $3.11B
- Shares Outstanding
- 74.7M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $20M
- Last Q Revenue
- $10M
- P/E Ratio
- 62.4
- P/S Ratio
- 6.3x
- EPS (TTM)
- $0.04
- Dividend Yield
- —
- Dilution (1yr)
- −0.2%
Why Investors Own HLP
- ✓High-growth profile — revenue up -5.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HONGLI GROUP INC
HLP
StockOtter · stockotter.spaceAbout HONGLI GROUP INC
Hongli Group Inc., through its affiliated entities, specializes in the engineering, tailoring, production, and distribution of cold roll-formed steel profiles. These precision components are utilized in a variety of machinery and equipment, with a market reach that extends across the People's Republic of China, South Korea, Japan, the United States, and Sweden. The company's products cater to essential sectors such as mining and excavation, construction, agriculture, and transportation. Established in 2021, the firm's corporate headquarters are situated in Weifang, China. Hongli Group Inc. operates as a subsidiary of Hongli Development Limited.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during T
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 2
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004
Hongli Group Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement
WEIFANG, China, Aug. 12, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on August 7, 2026, it received a notification letter from
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline d
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP's lead asset HLP003, an oral deuterated psilocin